Department of Pathophysiology and Transplantation, Ca' Granda Foundation and Institute for Research and Care, Maggiore Polyclinic Hospital, University of Milan, Milan, Italy.
MySkin Dermatology Practice, Tiggiano, Lecce, Italy.
G Ital Dermatol Venereol. 2019 Jun;154(3):342-346. doi: 10.23736/S0392-0488.17.05623-1.
Seborrheic dermatitis (SD) is a very common inflammatory skin disease. It occurs in 1-3% of the population. The most supported pathogenetic theory links SD to dandruff via a common etiology, yeasts of the genus Malassezia. Ketoconazole and ciclopirox (CPX) shampoo are considered as the first line treatment of SD of the scalp. CPX is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent with anti-bacterial, anti-inflammatory, and anti-oxidant properties. The aim of this study was to assess the efficacy and tolerability of 1% CPX shampoo in SD of the scalp.
A total of 40 patients, 31 men and 9 women, mean age 33±6 years, with scalp SD of moderate-to-severe grade were enrolled, after their informed consent, in this 12-week prospective assessor-blinded trial. One-percent CPX shampoo (5 mL) was applied twice a week for 12 weeks. The primary efficacy parameter was the Total Dandruff Severity Score (TDSS), based on 4-point ordinal scales describing signs and symptoms (scaling, inflammation, and itching) of the disease, evaluated in an assessor-blinded fashion, at baseline and after 6 and 12 weeks. Secondary outcomes were the single items of the TDSS and the evaluation of local tolerability.
At baseline the TDSS was 17±5. After 1% CPX TDSS was reduced to 10±5 at week 6 and to 6.6±4 at the end of study period (P=0.0001; ANOVA test). This difference represents a 62% reduction in comparison with baseline. At week 12, the reduction of scaling, inflammation and itching scores were -55%, -65%, and -69%, respectively. The product was very well tolerated. No side effects were reported or observed during the study.
The study supports the use of 1% CPX shampoo in the treatment of SD of the scalp. CPX shampoo was able to reduce desquamation, inflammation and itching associated with scalp SD. Furthermore, 1% CPX shampoo was found to be safe and well tolerated.
脂溢性皮炎(SD)是一种非常常见的炎症性皮肤病。它发生在 1-3%的人群中。最支持的发病理论将 SD 通过共同病因与头皮屑联系起来,即糠秕马拉色菌。酮康唑和环吡酮(CPX)洗发水被认为是头皮 SD 的一线治疗药物。CPX 是一种广谱、羟吡啶衍生的合成抗真菌剂,具有抗细菌、抗炎和抗氧化特性。本研究旨在评估 1%CPX 洗发水治疗头皮 SD 的疗效和耐受性。
共有 40 名患者,31 名男性和 9 名女性,平均年龄 33±6 岁,患有中重度头皮 SD,在知情同意后,参加了这项为期 12 周的前瞻性评估者盲法试验。每周两次使用 1%CPX 洗发水(5 毫升),持续 12 周。主要疗效参数是总头皮屑严重程度评分(TDSS),基于 4 点有序量表描述疾病的体征和症状(鳞屑、炎症和瘙痒),以盲法评估,在基线和 6 周和 12 周后评估。次要结局是 TDSS 的单个项目和局部耐受性评估。
基线时 TDSS 为 17±5。使用 1%CPX 后,TDSS 在第 6 周降至 10±5,在研究结束时降至 6.6±4(P=0.0001;方差分析)。与基线相比,这一差异代表了 62%的减少。第 12 周时,鳞屑、炎症和瘙痒评分分别减少了 55%、65%和 69%。该产品具有很好的耐受性。在研究期间未报告或观察到任何不良反应。
本研究支持使用 1%CPX 洗发水治疗头皮 SD。CPX 洗发水能够减少头皮 SD 相关的脱屑、炎症和瘙痒。此外,1%CPX 洗发水被发现是安全且耐受良好的。